LOGIN  |  REGISTER
Astria Therapeutics
Astria Therapeutics

RadNet to Present at the Raymond James 45th Annual Institutional Investors Conference Today, March 4th, 2024

March 04, 2024 | Last Trade: US$69.84 0.00 0.00

LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the Raymond James 45th Annual Institutional Investors Conference in Orlando, Florida today, Monday, March 4, 2024 at 3:25 p.m. Eastern Time.

A live webcast of RadNet's presentation can be accessed through the following link, https://wsw.com/webcast/rj129/rdnt/1616960 and is available for replay viewing. The Raymond James 45th Annual Institutional Investors Conference will take place at the JW Marriott Grande Lakes, Orlando.

Details for RadNet's Presentation:
Date:
Time:
Location:
Monday, March 4th, 2024
3:25 p.m. Eastern Time
JW Marriott Grande Lakes, Orlando, FL

About RadNet, Inc.

RadNet, Inc., is the leading national provider of free-standing, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 366 owned and/or operated outpatient imaging centers. RadNet's markets include California, Maryland, Delaware, New Jersey, New York, Florida, and Arizona. Together with affiliated radiologists, including full-time and per diem employees and technologists, RadNet has over 9,700 employees.

For more information, visit http://www.radnet.com.

Contact:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2800

Viking Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB